# PAKT: AZD5363 in Combination With Paclitaxel in Triple-Negative Advanced or Metastatic Breast Cancer

> **NCT02423603** · PHASE2 · COMPLETED · sponsor: **Queen Mary University of London** · enrollment: 71 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Paclitaxel
- **DRUG:** AZD5363
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02423603
- **Lead sponsor:** Queen Mary University of London
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05-14
- **Primary completion:** 2017-06-30
- **Final completion:** 2024-06-30
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2025-03-10

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02423603

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02423603, "PAKT: AZD5363 in Combination With Paclitaxel in Triple-Negative Advanced or Metastatic Breast Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT02423603. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*